Clinical trial · Interventional
Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma
NCT01569204CI-TRIAL-00035498completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Purpose of this trial is: * to determine complete response rate (CRR) after six cycles of chemotherapy * to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin Lymphoma | Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brentuximab Vedotin | Drug | Brentuximab Vedotin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Dacarbazine | Drug | Dacarbazine | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Prednisone | Drug | Prednisone | ALIAS |
| Procarbazine | Drug | Procarbazine | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- BrECAPP
- description
- modified BEACOPP by omitting Bleomycin and adding Brentuximab Vedotin
- interventionNames
- Drug: Etoposide
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Prednisone
- Drug: Procarbazine
- Drug: Brentuximab Vedotin
- type
- ACTIVE_COMPARATOR
- label
- BrECADD
- description
- modified BEACOPP by omitting Bleomycin, Procarbazine and Prednisone and adding Brentuximab Vedotin, Dacarbazine and Dexamethasone
- interventionNames
- Drug: Etoposide
- Drug: Cyclophosphamide
- Drug: Doxorubicin
- Drug: Dexamethasone
- Drug: Dacarbazine
- Drug: Brentuximab Vedotin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically proven classical Hodgkin lymphoma * First diagnosis, no previous treatment, age: 18-60 years * Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease Exclusion Criteria: * Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL) * Previous malignancy * Prior chemotherapy or radiation
References
Publications (0)
Data not yet available
No reference posted for this study.